Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group. Kellokumpu-Lehtinen PL, et al. Among authors: lehtinen i. Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4. Lancet Oncol. 2013. PMID: 23294853 Clinical Trial.
A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjöström-Mattson J; Finnish Breast Cancer Group. Kellokumpu-Lehtinen PL, et al. Among authors: lehtinen i. Clin Breast Cancer. 2006 Dec;7(5):401-5. doi: 10.3816/cbc.2006.n.057. Clin Breast Cancer. 2006. PMID: 17239265 Clinical Trial.
Weekly paclitaxel--an effective treatment for advanced breast cancer.
Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R, Järvenpää R, Lehtinen I, Maiche A, Kaleva-Kerola J, Huusko M, Möykkynen K, Ala-Luhtala T. Kellokumpu-Lehtinen P, et al. Among authors: lehtinen i. Anticancer Res. 2013 Jun;33(6):2623-7. Anticancer Res. 2013. PMID: 23749918
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M, Sormunen J, Luukkaala T, Marttila T, McDermott R, Joensuu T, Lehtinen I, Ginman C, Kellokumpu-Lehtinen PL. Lehtonen M, et al. Among authors: lehtinen i. Acta Oncol. 2022 Aug;61(8):963-971. doi: 10.1080/0284186X.2022.2098680. Epub 2022 Jul 18. Acta Oncol. 2022. PMID: 35847998 Clinical Trial.
Health-related Quality of Life of Patients Treated With Different Fractionation Schedules for Early Prostate Cancer Compared to the Age-standardized General Male Population.
Reinikainen P, Lehtonen M, Lehtinen I, Luukkaala T, Sintonen H, Kellokumpu-Lehtinen PL. Reinikainen P, et al. Among authors: lehtinen i. Clin Genitourin Cancer. 2023 Feb;21(1):146-154. doi: 10.1016/j.clgc.2022.07.013. Epub 2022 Aug 3. Clin Genitourin Cancer. 2023. PMID: 36038484 Free article.
37 results